GlassScriptPhysician profile
Alicia Vatter
NPI 1265107023
$14,998.49
in general payments reported to CMS, 2019-2025
26 companies · $3,070 in 2025
The $3,070 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $437 · 2022: $2,335 · 2023: $3,790 · 2024: $5,367 · 2025: $3,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,761.37 |
| Education | $465.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,913.85 | 2021-2025 | |
| Janssen Biotech, INC. | $2,588.95 | 2021-2025 | Tremfya |
| Leo Pharma INC. | $1,222.82 | 2021-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $916.46 | 2021-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $869.47 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $791.08 | 2021-2025 | |
| Pfizer INC. | $714.23 | 2022-2025 | |
| Amgen INC. | $645.33 | 2021-2025 | Otezla, Otezla |
| Incyte Corporation | $621.24 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $615.49 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $558.61 | 2022-2025 | Winlevi, Absorica Ld, Ilumya |
| Ucb, INC. | $551.62 | 2022-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $428.60 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $417.68 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $357.97 | 2021-2025 | Siliq, Targretin, Duobrii |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $289.96 | 2023-2025 | Aklief, Nemluvio, Oracea |
| Janssen Scientific Affairs, LLC | $115.01 | 2022 | |
| Organon LLC | $112.39 | 2024-2025 | Vtama, Hadlima |
| Journey Medical Corporation | $79.65 | 2023-2024 | |
| Kyowa Kirin, INC. | $47.40 | 2022 | |
| Dermavant Sciences, INC. | $29.61 | 2023 | Vtama |
| Strata Skin Sciences, INC. | $29.34 | 2025 | Xtrac |
| Merz North America, INC. | $24.16 | 2023 | Xeomin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.85 | 2024 | Cyltezo |
| Lnhc, INC | $18.23 | 2025 | Zelsuvmi |
| Verrica Pharmaceuticals INC. | $16.49 | 2023 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alicia Vatter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.